

# David Jayne

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2377403/david-jayne-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

143  
papers

7,077  
citations

37  
h-index

82  
g-index

182  
ext. papers

9,143  
ext. citations

5.1  
avg. IF

5.79  
L-index

#	Paper	IF	Citations
143	Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis.. <i>Annals of the Rheumatic Diseases</i> , <b>2022</b> ,	2.4	8
142	Alemtuzumab for refractory primary systemic vasculitis-a randomised controlled dose ranging clinical trial of efficacy and safety (ALEVIATE).. <i>Arthritis Research and Therapy</i> , <b>2022</b> , 24, 81	5.7	0
141	An international Delphi exercise to identify items of importance for measuring response to treatment in ANCA-associated vasculitis.. <i>Seminars in Arthritis and Rheumatism</i> , <b>2022</b> , 55, 152021	5.3	
140	Synthesis and pharmacological characterisation of arctigenin analogues as antagonists of AMPA and kainate receptors. <i>Organic and Biomolecular Chemistry</i> , <b>2021</b> , 19, 9154-9162	3.9	0
139	Pharmacological characterization of a novel negative allosteric modulator of NMDA receptors, UBP792. <i>Neuropharmacology</i> , <b>2021</b> , 201, 108818	5.5	
138	Multiple roles of GluN2D-containing NMDA receptors in short-term potentiation and long-term potentiation in mouse hippocampal slices. <i>Neuropharmacology</i> , <b>2021</b> , 201, 108833	5.5	3
137	Incidence and predictors of severe infections in ANCA-associated vasculitis: a population-based cohort study. <i>Rheumatology</i> , <b>2021</b> , 60, 2745-2754	3.9	5
136	ANCA-Associated Vasculitis: An Update. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	13
135	Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: development and initial validation in a cohort of 220 patients. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 1175-1182	2.4	2
134	PR3-ANCA associated retinal vasculitis and atrial myxoma. <i>Rheumatology</i> , <b>2021</b> , 60, e5-e6	3.9	
133	Renal involvement in eosinophilic granulomatosis with polyangiitis (EGPA): a multicentric retrospective study of 63 biopsy-proven cases. <i>Rheumatology</i> , <b>2021</b> , 60, 359-365	3.9	10
132	Heart disease in eosinophilic granulomatosis with polyangiitis (EGPA) patients: a screening approach proposal. <i>Rheumatology</i> , <b>2021</b> , 60, 4538-4547	3.9	1
131	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	10
130	Developing a composite outcome tool to measure response to treatment in ANCA-associated vasculitis: A mixed methods study from OMERACT 2020. <i>Seminars in Arthritis and Rheumatism</i> , <b>2021</b> , 51, 1134-1138	5.3	2
129	Urinary MCP-1 and TWEAK as non-invasive markers of disease activity and treatment response in patients with lupus nephritis in South Africa. <i>International Urology and Nephrology</i> , <b>2021</b> , 53, 1865-1873	2.3	0
128	Venous thromboembolism in ANCA-associated vasculitis: a population-based cohort study. <i>Rheumatology</i> , <b>2021</b> , 60, 4616-4623	3.9	4
127	Increasing incidence and improved survival in ANCA-associated vasculitis-a Danish nationwide study. <i>Nephrology Dialysis Transplantation</i> , <b>2020</b> ,	4.3	4

126	Is There a Role for LAMP-2 Autoantibodies in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis?. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 636-638	4.1	
125	Comment on: Subclassifying ANCA-associated vasculitis: a unifying view of disease spectrum: reply. <i>Rheumatology</i> , <b>2020</b> , 59, 1187	3.9	
124	Structural basis of subtype-selective competitive antagonism for GluN2C/2D-containing NMDA receptors. <i>Nature Communications</i> , <b>2020</b> , 11, 423	17.4	10
123	"In my beginning is my end": usefulness of repeat kidney biopsies in lupus nephritis. <i>Kidney International</i> , <b>2020</b> , 97, 27-29	9.9	3
122	2020 international consensus on ANCA testing beyond systemic vasculitis. <i>Autoimmunity Reviews</i> , <b>2020</b> , 19, 102618	13.6	36
121	A case of type B insulin resistance presenting at a district general hospital. <i>Practical Diabetes</i> , <b>2020</b> , 37, 93-95	0.7	
120	Use and reporting of outcome measures in randomized trials for anti-neutrophil cytoplasmic antibody-associated vasculitis: a systematic literature review. <i>Seminars in Arthritis and Rheumatism</i> , <b>2020</b> , 50, 1314-1325	5.3	6
119	Guidelines on the use of irradiated blood components. <i>British Journal of Haematology</i> , <b>2020</b> , 191, 704-724	4.5	25
118	Response to: Prevention of infections in patients with antineutrophil cytoplasm antibody-associated vasculitis: potential role of hydroxychloroquine by Novikov. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, e20	2.4	2
117	Response to: Mycophenolate mofetil: a step forward in the induction treatment of ANCA-associated vasculitis? Comment on the article by Jones by Vandergheynst. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, e101	2.4	
116	Integrated safety profile of atacicept: an analysis of pooled data from the atacicept clinical trial programme. <i>Rheumatology Advances in Practice</i> , <b>2019</b> , 3, rkz021	1.1	2
115	322. A RANDOMISED, DOUBLE-BLIND, CONTROLLED, MECHANISTIC STUDY OF RITUXIMAB AND BELIMUMAB COMBINATION THERAPY IN PR3 ANCA-ASSOCIATED VASCULITIS (COMBIVAS): STUDY PROTOCOL. <i>Rheumatology</i> , <b>2019</b> , 58,	3.9	7
114	Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 634-640	2.4	35
113	Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2019</b> , 143, 2170-2177	11.5	41
112	Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis. <i>RMD Open</i> , <b>2019</b> , 5, e000905	5.9	37
111	361. THE EFFECT OF REDUCED-DOSE ORAL GLUCOCORTICOIDS DURING INDUCTION OF REMISSION INDUCTION IN SEVERE ANCA-ASSOCIATED VASCULITIS. <i>Rheumatology</i> , <b>2019</b> , 58,	3.9	3
110	Systemic vasculitis and patient-reported outcomes: how the assessment of patient preferences and perspectives could improve outcomes. <i>Patient Related Outcome Measures</i> , <b>2019</b> , 10, 37-42	2.9	4
109	2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 736-745	2.4	628

108	Genetic Variants in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Bayesian Approach and Systematic Review. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,	5.1	12
107	Proteinase-3 and myeloperoxidase serotype in relation to demographic factors and geographic distribution in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis. <i>Nephrology Dialysis Transplantation</i> , <b>2019</b> , 34, 301-308	4.3	10
106	New perspectives in eosinophilic granulomatosis with polyangiitis (EGPA): report of the first meeting of the European EGPA Study Group. <i>Internal and Emergency Medicine</i> , <b>2019</b> , 14, 1193-1197	3.7	8
105	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1151-1159	2.4	344
104	ANCA associated vasculitis: The journey to complement-targeted therapies. <i>Molecular Immunology</i> , <b>2019</b> , 112, 394-398	4.3	11
103	296. PLASMA EXCHANGE AS A NOVEL TREATMENT FOR IGA VASCULITIS WITH NEPHRITIS. <i>Rheumatology</i> , <b>2019</b> , 58,	3.9	1
102	Comment on: A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis: reply. <i>Rheumatology</i> , <b>2019</b> , 58, 738-739	3.9	1
101	Complement inhibition in ANCA vasculitis. <i>Nephrologie Et Therapeutique</i> , <b>2019</b> , 15, 409-412	0.6	14
100	Iatrogenic antibody deficiency from B-cell targeted therapies in autoimmune rheumatic diseases. <i>Lupus Science and Medicine</i> , <b>2019</b> , 6, e000337	4.6	3
99	The relapsing polychondritis damage index (RPDAM): Development of a disease-specific damage score for relapsing polychondritis. <i>Joint Bone Spine</i> , <b>2019</b> , 86, 363-368	2.9	4
98	Investigation of the structural requirements for N-methyl-D-aspartate receptor positive and negative allosteric modulators based on 2-naphthoic acid. <i>European Journal of Medicinal Chemistry</i> , <b>2019</b> , 164, 471-498	6.8	8
97	Assembly and Trafficking of Homomeric and Heteromeric Kainate Receptors with Impaired Ligand Binding Sites. <i>Neurochemical Research</i> , <b>2019</b> , 44, 585-599	4.6	5
96	Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 399-405	2.4	102
95	The NMDA receptor intracellular C-terminal domains reciprocally interact with allosteric modulators. <i>Biochemical Pharmacology</i> , <b>2019</b> , 159, 140-153	6	6
94	Positive and Negative Allosteric Modulators of N-Methyl-d-aspartate (NMDA) Receptors: Structure-Activity Relationships and Mechanisms of Action. <i>Journal of Medicinal Chemistry</i> , <b>2019</b> , 62, 3-23	8.3	27
93	Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , <b>2019</b> , 34, 63-73	4.3	47
92	A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis. <i>Rheumatology</i> , <b>2019</b> , 58, 260-268	3.9	19
91	Targeting B Cells and Plasma Cells in Glomerular Diseases: Translational Perspectives. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2018</b> , 29, 741-758	12.7	26

90	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: Executive Summary. <i>Rheumatology</i> , <b>2018</b> , 57, 14-18	3.9	23
89	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. <i>Rheumatology</i> , <b>2018</b> , 57, e1-e45	3.9	150
88	A retrospective study comparing the phenotype and outcomes of patients with polyarteritis nodosa between UK and Turkish cohorts. <i>Rheumatology International</i> , <b>2018</b> , 38, 1833-1840	3.6	9
87	B cell therapy in ANCA-associated vasculitis: current and emerging treatment options. <i>Nature Reviews Rheumatology</i> , <b>2018</b> , 14, 580-591	8.1	39
86	Some distorted thoughts about ketamine as a psychedelic and a novel hypothesis based on NMDA receptor-mediated synaptic plasticity. <i>Neuropharmacology</i> , <b>2018</b> , 142, 30-40	5.5	20
85	Comment on: The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: reply. <i>Rheumatology</i> , <b>2018</b> , 57, 1502-1503	3.9	7
84	Putative Receptors Underpinning l-Lactate Signalling in Locus Coeruleus. <i>Neuroglia (Basel, Switzerland)</i> , <b>2018</b> , 1, 365-380		10
83	Long-term outcomes of patients with Takayasu arteritis and renal artery involvement: a cohort study. <i>Rheumatology Advances in Practice</i> , <b>2018</b> , 2, rky026	1.1	8
82	SaO020RITUXIMAB AS MAINTENANCE THERAPY FOR SYSTEMIC LUPUS ERYTHEMATOSUS. <i>Nephrology Dialysis Transplantation</i> , <b>2018</b> , 33, i323-i323	4.3	
81	Comparisons of Guidelines and Recommendations on Managing Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Kidney International Reports</i> , <b>2018</b> , 3, 1039-1049	4.1	25
80	Clinical associations with venous thromboembolism in anti-neutrophil cytoplasm antibody-associated vasculitides. <i>Rheumatology</i> , <b>2017</b> , 56, 704-708	3.9	16
79	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 554-561	2.4	175
78	The Startle Disease Mutation E103K Impairs Activation of Human Homomeric $\alpha$ Glycine Receptors by Disrupting an Intersubunit Salt Bridge across the Agonist Binding Site. <i>Journal of Biological Chemistry</i> , <b>2017</b> , 292, 5031-5042	5.4	7
77	A case of de novo diagnosis anti-neutrophil cytoplasmic antibody-negative pauci-immune necrotising glomerulonephritis in pregnancy. <i>Internal Medicine Journal</i> , <b>2017</b> , 47, 600-601	1.6	5
76	Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 1921-1932	59.2	416
75	Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 1662-1668	2.4	100
74	Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse. <i>Arthritis Research and Therapy</i> , <b>2017</b> , 19, 129	5.7	26
73	The European Vasculitis Society 2016 Meeting Report. <i>Kidney International Reports</i> , <b>2017</b> , 2, 1018-1031	4.1	17

72	Vasculitis-when can biopsy be avoided?. <i>Nephrology Dialysis Transplantation</i> , <b>2017</b> , 32, 1454-1456	4.3	8
71	Position paper: Revised 2017 international consensus on testing of ANCA in granulomatosis with polyangiitis and microscopic polyangiitis. <i>Nature Reviews Rheumatology</i> , <b>2017</b> , 13, 683-692	8.1	183
70	Mechanism and properties of positive allosteric modulation of N-methyl-d-aspartate receptors by 6-alkyl 2-naphthoic acid derivatives. <i>Neuropharmacology</i> , <b>2017</b> , 125, 64-79	5.5	14
69	A single-channel mechanism for pharmacological potentiation of GluN1/GluN2A NMDA receptors. <i>Scientific Reports</i> , <b>2017</b> , 7, 6933	4.9	7
68	Lupus nephritis and B-cell targeting therapy. <i>Expert Review of Clinical Immunology</i> , <b>2017</b> , 13, 951-962	5.1	17
67	A genome-wide association study suggests the HLA Class II region as the major susceptibility locus for IgA vasculitis. <i>Scientific Reports</i> , <b>2017</b> , 7, 5088	4.9	31
66	The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales. <i>Rheumatology</i> , <b>2017</b> , 56, 1041-1043	3.9	1
65	Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): A study of 157 patients by the Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires and the European Respiratory Society Taskforce on eosinophilic granulomatosis with polyangiitis (Churg-Strauss). <i>Autoimmunity Reviews</i> , <b>2017</b> , 16, 1-9	13.6	98
64	Multiple roles of GluN2B-containing NMDA receptors in synaptic plasticity in juvenile hippocampus. <i>Neuropharmacology</i> , <b>2017</b> , 112, 76-83	5.5	22
63	Progressive multifocal leucoencephalopathy with Behçet's disease: an insight into pathophysiology. <i>Rheumatology</i> , <b>2017</b> , 56, 668-670	3.9	0
62	End-stage renal disease in ANCA-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , <b>2017</b> , 32, 248-253	4.3	37
61	Development of a score for assessment of radiologic damage in large-vessel vasculitis (Combined Arteritis Damage Score, CARDS). <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35 Suppl 103, 139-145	2.2	10
60	Clinical Trials in Vasculitis. <i>Current Treatment Options in Rheumatology</i> , <b>2016</b> , 2, 161-177	1.3	5
59	Sustained remission in lupus nephritis: still a hard road ahead. <i>Nephrology Dialysis Transplantation</i> , <b>2016</b> , 31, 2011-2018	4.3	11
58	Outcome assessment in Takayasu arteritis. <i>Rheumatology</i> , <b>2016</b> , 55, 1159-71	3.9	21
57	MO040ASSOCIATION OF A TNFSF13B (BAFF) REGULATORY REGION SINGLE NUCLEOTIDE POLYMORPHISMS WITH RESPONSE TO RITUXIMAB IN ANCA-ASSOCIATED VASCULITIS. <i>Nephrology Dialysis Transplantation</i> , <b>2016</b> , 31, i45-i46	4.3	
56	TO039RISK OF VENOUS THROMBOEMBOLIC EVENTS IN ANCA ASSOCIATED VASCULITIS. <i>Nephrology Dialysis Transplantation</i> , <b>2016</b> , 31, i77-i78	4.3	
55	Long-Term Followup of a Multicenter Cohort of 101 Patients With Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss). <i>Arthritis Care and Research</i> , <b>2016</b> , 68, 374-87	4.7	56

54	Prevalence and Responsiveness to Treatment of Lung Abnormalities on Chest Computed Tomography in Patients With Microscopic Polyangiitis: A Multicenter, Longitudinal, Retrospective Study of One Hundred Fifty Consecutive Hospital-Based Japanese Patients. <i>Arthritis and Rheumatology</i> , <b>2016</b> , 68, 713-23	9.5	28
53	Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). <i>European Respiratory Journal</i> , <b>2016</b> , 48, 1429-1441	13.6	61
52	Predictors of renal and patient outcomes in anti-GBM disease: clinicopathologic analysis of a two-centre cohort. <i>Nephrology Dialysis Transplantation</i> , <b>2015</b> , 30, 814-21	4.3	58
51	Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. <i>European Journal of Internal Medicine</i> , <b>2015</b> , 26, 545-553	3.9	254
50	Twenty-five years of European Union collaboration in ANCA-associated vasculitis research. <i>Nephrology Dialysis Transplantation</i> , <b>2015</b> , 30 Suppl 1, i1-7	4.3	14
49	Synthesis of a Series of Novel 3,9-Disubstituted Phenanthrenes as Analogues of Known NMDA Receptor Allosteric Modulators. <i>Synthesis</i> , <b>2015</b> , 47, 1593-1610	2.9	7
48	2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1799-807	2.4	127
47	Clinical features and radiological findings in large vessel vasculitis: are Takayasu arteritis and giant cell arteritis 2 different diseases or a single entity?. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 300-8	4.1	42
46	Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 177-84	2.4	143
45	An interchangeable role for kainate and metabotropic glutamate receptors in the induction of rat hippocampal mossy fiber long-term potentiation in vivo. <i>Hippocampus</i> , <b>2015</b> , 25, 1407-17	3.5	5
44	Characteristics and Outcomes of Granulomatosis With Polyangiitis (Wegener) and Microscopic Polyangiitis Requiring Renal Replacement Therapy: Results From the European Renal Association-European Dialysis and Transplant Association Registry. <i>American Journal of Kidney Diseases</i> , <b>2015</b> , 66, 613-20	7.4	37
43	2015 recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. <i>Arthritis and Rheumatology</i> , <b>2015</b> , 67, 2569-80	9.5	58
42	Long-term potentiation and the role of N-methyl-D-aspartate receptors. <i>Brain Research</i> , <b>2015</b> , 1621, 5-16	3.7	151
41	Elicitation of expert prior opinion: application to the MYPAN trial in childhood polyarteritis nodosa. <i>PLoS ONE</i> , <b>2015</b> , 10, e0120981	3.7	29
40	Gating Effects of a Novel Allosteric Modulator at GluN1/GluN2A NMDA Receptors. <i>FASEB Journal</i> , <b>2015</b> , 29, 933.3	0.9	
39	Biologic treatment in glomerular disease. <i>Nephron Clinical Practice</i> , <b>2014</b> , 128, 203-4		1
38	ANCA serotype and histopathological classification for the prediction of renal outcome in ANCA-associated glomerulonephritis. <i>Nephrology Dialysis Transplantation</i> , <b>2014</b> , 29, 1764-9	4.3	76
37	BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. <i>Rheumatology</i> , <b>2014</b> , 53, 2306-9	3.9	186

36	Long-term outcome of airway stenosis in granulomatosis with polyangiitis (Wegener granulomatosis): an observational study. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , <b>2014</b> , 140, 1038-44	3.9	23
35	New-generation therapy for ANCA-associated vasculitis. <i>Clinical and Experimental Nephrology</i> , <b>2013</b> , 17, 694-696	2.5	5
34	S2. Rituximab for ANCA-associated vasculitis: the UK experience. <i>Presse Medicale</i> , <b>2013</b> , 42, 532-4	2.2	2
33	L27. Antibodies versus phenotypes: a clinician's view. <i>Presse Medicale</i> , <b>2013</b> , 42, 579-82	2.2	5
32	The NMDA receptor as a target for cognitive enhancement. <i>Neuropharmacology</i> , <b>2013</b> , 64, 13-26	5.5	175
31	Structure-activity relationships for allosteric NMDA receptor inhibitors based on 2-naphthoic acid. <i>Neuropharmacology</i> , <b>2012</b> , 62, 1730-6	5.5	29
30	Coumarin-3-carboxylic acid derivatives as potentiators and inhibitors of recombinant and native N-methyl-D-aspartate receptors. <i>Neurochemistry International</i> , <b>2012</b> , 61, 593-600	4.4	29
29	Pharmacological modulation of NMDA receptor activity and the advent of negative and positive allosteric modulators. <i>Neurochemistry International</i> , <b>2012</b> , 61, 581-92	4.4	67
28	Treating vasculitis with conventional immunosuppressive agents. <i>Cleveland Clinic Journal of Medicine</i> , <b>2012</b> , 79 Suppl 3, S46-9	2.8	7
27	A novel family of negative and positive allosteric modulators of NMDA receptors. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2010</b> , 335, 614-21	4.7	75
26	Allosteric block of KCa2 channels by apamin. <i>Journal of Biological Chemistry</i> , <b>2010</b> , 285, 27067-27077	5.4	55
25	Role of rituximab therapy in glomerulonephritis. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2010</b> , 21, 14-7	12.7	33
24	The diagnosis of vasculitis. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2009</b> , 23, 445-53	5.3	50
23	The vasculitic diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2009</b> , 23, 305-7	5.3	0
22	Treatment of ANCA-associated systemic small-vessel vasculitis. <i>Apmis</i> , <b>2009</b> , 117, 3-9	3.4	9
21	Review article: Progress of treatment in ANCA-associated vasculitis. <i>Nephrology</i> , <b>2009</b> , 14, 42-8	2.2	39
20	Kainate receptors: pharmacology, function and therapeutic potential. <i>Neuropharmacology</i> , <b>2009</b> , 56, 90-113	5.5	211
19	Challenges in the management of microscopic polyangiitis: past, present and future. <i>Current Opinion in Rheumatology</i> , <b>2008</b> , 20, 3-9	5.3	28



18	The glutamate story. <i>British Journal of Pharmacology</i> , <b>2006</b> , 147 Suppl 1, S100-8	8.6	182
17	How to induce remission in primary systemic vasculitis. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2005</b> , 19, 293-305	5.3	14
16	Autologous stem cell transplantation for systemic lupus erythematosus. <i>Lupus</i> , <b>2004</b> , 13, 168-76	2.6	143
15	Stem cell transplantation in systemic lupus erythematosus. <i>Best Practice and Research in Clinical Haematology</i> , <b>2004</b> , 17, 291-304	4.2	3
14	Characterisation of UBP296: a novel, potent and selective kainate receptor antagonist. <i>Neuropharmacology</i> , <b>2004</b> , 47, 46-64	5.5	87
13	The clinical features and pathology of vasculitis associated with anti-myeloperoxidase autoantibodies. <i>Japanese Journal of Infectious Diseases</i> , <b>2004</b> , 57, S16-7	2.7	3
12	Current attitudes to the therapy of vasculitis. <i>Kidney and Blood Pressure Research</i> , <b>2003</b> , 26, 231-9	3.1	30
11	Actions of LY341495 on metabotropic glutamate receptor-mediated responses in the neonatal rat spinal cord. <i>British Journal of Pharmacology</i> , <b>2003</b> , 139, 147-55	8.6	7
10	Phenylglycine derivatives as antagonists of group III metabotropic glutamate receptors expressed on neonatal rat primary afferent terminals. <i>British Journal of Pharmacology</i> , <b>2003</b> , 139, 1523-31	8.6	8
9	A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. <i>New England Journal of Medicine</i> , <b>2003</b> , 349, 36-44	59.2	1024
8	Synthesis and biological evaluation of phospholane and dihydrophosphole analogues of the glutamate receptor agonist AP4. <i>Journal of the Chemical Society, Perkin Transactions 1</i> , <b>2002</b> , 1625-1627		4
7	Clinical management and treatment of vasculitis. <i>Seminars in Immunopathology</i> , <b>2001</b> , 23, 267-86		6
6	Synthesis of willardiine and 6-azawillardiine analogs: pharmacological characterization on cloned homomeric human AMPA and kainate receptor subtypes. <i>Journal of Medicinal Chemistry</i> , <b>1997</b> , 40, 3645-50	8.3	96
5	Pharmacological antagonism of the actions of group II and III mGluR agonists in the lateral perforant path of rat hippocampal slices. <i>British Journal of Pharmacology</i> , <b>1996</b> , 117, 1457-62	8.6	87
4	The effects of (RS)-alpha-cyclopropyl-4-phosphonophenylglycine ((RS)-CPPG), a potent and selective metabotropic glutamate receptor antagonist. <i>British Journal of Pharmacology</i> , <b>1996</b> , 119, 851-4	8.6	69
3	(S)-homoquisqualate: a potent agonist at the glutamate metabotropic receptor. <i>British Journal of Pharmacology</i> , <b>1992</b> , 106, 509-10	8.6	27
2	The Excitatory Amino Acid System		67-84
1	Immune Vasculitis		1-8

